Peptides Similar to HGH 191AA

Peptides Related to HGH 191AA#

Several peptides share functional overlap with HGH 191AA in tissue repair and healing research. Below is a detailed comparison of their mechanisms, efficacy, and potential for combination use.

Thymosin Beta-4 (TB-500)#

We compared human evidence for HGH 191AA (somatropin), Thymosin beta‑4/TB‑500, and GHK‑Cu across wound/tendon/fracture healing, ocular surface disease, skin aging, and hair. We prioritized randomized or controlled human trials, extracted primary outcomes and safety, and noted head‑to‑head data availability. A side‑by‑side summary is embedded below.

Findings by domain Wound, burn, fracture, tendon, and rehabilitation

• HGH 191AA (systemic): Randomized trials demonstrate context‑specific effects. In severely burned children (>40% TBSA), long‑term rhGH improved linear growth, increased lean body mass, attenuated hypermetabolism, and improved scarring at 12 months versus placebo; dose‑related metabolic adverse events included hyperglycemia/glucose intolerance and hypercalcemia in a few patients (Ann Surg 2009). In healthy young men undergoing limb immobilization and rehabilitation, rhGH preserved tendon stiffness during immobilization and increased tendon stiffness during rehabilitation without measurable advantages in muscle mass or maximal strength over placebo, indicating matrix/tendon benefits more than contractile gains (J Physiol 2013). In contrast, two large multicenter ICU trials using high‑dose rhGH (~0.10 mg/kg/day) in critically ill adults increased in‑hospital mortality (relative risk about 1.9–2.4) and prolonged ventilator, ICU, and hospital days; hyperglycemia requiring insulin and more infections were reported (NEJM 1999). Head‑to‑head comparisons versus other peptides were not found.
• Thymosin beta‑4/TB‑500 (topical/systemic): Three phase 2 randomized, placebo‑controlled dermal wound trials (pressure ulcers, venous stasis ulcers, epidermolysis bullosa) showed early dose‑range trends toward faster healing but no statistically significant differences at primary endpoints by study completion; safety was favorable with good local tolerability and no systemic signals (Vitamins & Hormones review of trial data). No robust randomized human trials in tendon or fracture healing were identified. No head‑to‑head data versus HGH or GHK‑Cu were found.
• GHK‑Cu (topical): Human randomized trials focus on cosmetic anti‑aging; randomized wound‑healing trials in humans were not identified in the provided evidence. Therefore, for wound or tendon repair, controlled human evidence is insufficient here.

Ocular surface disease (dry eye disease, neurotrophic keratopathy, corneal defects)

• Thymosin beta‑4 (RGN‑259 ophthalmic): A small randomized trial reported improved tear film breakup time and tear volume; larger phase 2/3 dry‑eye programs (ARISE‑1/2/3) and NK programs have mixed or ongoing results; overall, signals of clinical activity exist with generally favorable ocular safety, though definitive efficacy across endpoints remains mixed at phase 3 (reviews summarizing trial programs). No head‑to‑head comparisons with other topical agents in controlled trials were identified in the curated evidence.
• HGH 191AA and GHK‑Cu: No randomized human ocular trials of rhGH or topical GHK‑Cu for DED/NK were identified in the retrieved evidence.

Skin aging and hair

• GHK‑Cu (topical): Randomized, double‑blind and split/comparator trials in cosmetic populations report significant reductions in wrinkle volume/depth (e.g., ~−26% to −32% at 8 weeks) and improvements in skin thickness/density and elasticity; in at least one study GHK‑Cu outperformed an active comparator (Matrixyl 3000) and vehicle on select endpoints; tolerability was good with rare mild local reactions. Controlled trials specifically assessing hair growth with GHK‑Cu were not identified in the extracted evidence.
• Thymosin beta‑4/TB‑500 and HGH 191AA: No randomized human trials for skin anti‑aging or hair outcomes were identified in the curated evidence.

Head‑to‑head data

• Across HGH 191AA, Thymosin beta‑4/TB‑500, and GHK‑Cu, we found no head‑to‑head randomized trials directly comparing these agents to each other in any domain.

Safety comparison

• HGH 191AA: Context‑dependent. Long‑term use in pediatric burns improved outcomes but produced dose‑related metabolic AEs (hyperglycemia/hypercalcemia). High‑dose use in critically ill adults increased mortality and morbidity, with hyperglycemia and more infections—highlighting clear harm at ICU‑level dosing and setting.

• Thymosin beta‑4/TB‑500: Across phase 2 topical and ophthalmic trials, generally well tolerated; no systemic safety signals; bell‑shaped dose–response suggested in preclinical work.

• GHK‑Cu: Cosmetic studies report good tolerability with occasional mild local reactions; robust systemic safety data are sparse because application is topical and durations are short‑term.

• For tissue repair in humans, rhGH (191aa) shows randomized evidence of benefit in specific contexts (pediatric severe burns; tendon stiffness during immobilization/rehab) but is harmful at high doses in critically ill adults; careful indication and dosing are paramount. Thymosin beta‑4/TB‑500 has phase 2 randomized data in dermal ulcers with no sustained primary endpoint superiority despite early trends; ocular (RGN‑259) programs show signals but mixed phase 3 results to date. GHK‑Cu has moderate‑quality randomized cosmetic evidence supporting wrinkle and dermal matrix improvements but lacks controlled human trials for wound/tendon or hair in the curated corpus. No head‑to‑head comparisons among these three agents were identified.

Implications for practice and research

• If the goal is musculoskeletal or tendon support during rehabilitation in otherwise healthy subjects, rhGH shows tendon‑stiffness benefits but not strength/mass gains; risk–benefit must consider metabolic AEs and is not generalizable to critical illness. For chronic cutaneous ulcers, Tβ4 topical has not met primary endpoints in RCTs despite early signals; further dose‑finding and formulation work may be needed (kleinman2016thymosinβ4promotes pages 14-17). For cosmetic anti‑aging, topical GHK‑Cu has the most consistent randomized human improvement signals with good tolerability among the three, albeit in cosmetic—not reparative—indications. Direct comparative trials are an unmet need.

Mechanism Comparison#

Which peptides share overlapping mechanisms?

• Exact overlap at the receptor/signaling level: somatropin, somapacitan, and somatrogon (all GHR agonists; JAK2→STAT5±MAPK/PI3K).
• Overlap within upstream GPCR secretagogues: tesamorelin and CJC-1295 (both GHRH-R, Gs/cAMP/PKA±MAPK); ipamorelin and macimorelin (both GHSR1a, Gq/Gi with β-arrestin). Although these two GPCR groups use different immediate second messengers, both converge physiologically by increasing pituitary GH, leading to shared downstream GHR→STAT5/IGF-1 effects.
• Partial downstream overlap without receptor overlap: mecasermin shares PI3K/AKT and MAPK/ERK with GH-induced IGF-1 actions but operates via IGF1R rather than GHR.
• No documented overlap: GH fragment 176–191 (AOD-9604) shows no evidence of engaging GHR or IGF1R or elevating IGF-1.

Embedded comparison summary

Combination and Synergy#

We synthesized the available preclinical, clinical, and mechanistic literature for combinations of recombinant human growth hormone (HGH; somatropin, 191 aa) with healing peptides.

Evidence by combination

GH + IGF‑1: In glucocorticoid‑treated mdx mice, co‑administration of GH and IGF‑1 rescued somatic growth retardation and improved grip strength, although it did not improve bone microarchitecture. These data support complementary/additive effects for growth and muscle function but not for bone in this model. Reviews of tendon biology further indicate that IGF‑1 combined with other growth factors enhances collagen synthesis and tenocyte function, consistent with a role for GH→IGF‑1 signaling in matrix repair, though these tendon studies did not co‑administer exogenous GH with IGF‑1.

GH + GLP‑2 (teduglutide) and intestinal adaptation: Clinical data consistently support GLP‑2 analogs for enhancing intestinal absorption and adaptation in short bowel syndrome, whereas GH has been used historically, often paired with glutamine and nutritional strategies. However, direct trials combining GH with GLP‑2 are not established in the evidence reviewed; the combination remains theoretically complementary (distinct mechanisms) but presently unsupported by controlled combination trials pages 23-25).

GH + glutamine in short bowel syndrome: Several studies and reviews report increased intestinal nitrogen absorption and short‑term body weight/lean mass gains when GH was used with glutamine; however, later controlled trials showed mixed outcomes, indicating that any complementarity is inconsistent and context‑dependent.

GH + GHRH/ghrelin analogs (secretagogues): Multiple human studies demonstrate that combining a GHRH analog with a GHRP (e.g., GHRP‑6) produces synergistic GH release versus single agents, and prolonged GHRP infusion increases pulsatile GH and serum IGF‑1. This is clear endocrine synergy for stimulating endogenous GH/IGF‑1. Notably, these studies do not co‑administer exogenous somatropin with secretagogues; rather, they document synergy among secretagogues themselves.

GH + EGF/FGF or other growth factors (in vitro): Wound‑healing literature includes in vitro experiments where rhGH combined with EGF/FGF altered fibroblast behavior toward proliferative/wound repair phenotypes, suggesting mechanistic complementarity of GH with other growth factors, though translational combination data are limited (caicedo2019growthhormone(gh) pages 23-25).

GH + BPC‑157 or thymosin β4/TB‑500: We found no controlled preclinical or clinical studies directly combining rhGH with BPC‑157 or TB‑500. Reviews and slide‑deck style sources assert that BPC‑157 may upregulate GH receptor expression and share angiogenic pathways, implying mechanistic complementarity, but they do not present controlled GH+BPC‑157 combination outcomes. Therefore, synergy remains unproven for these pairings (clearfieldUnknownyearimmunemodulatingpeptides pages 1-27).

• Demonstrated complementary/additive effects: GH+IGF‑1 in mdx mice improved growth and muscle function but not bone structure (preclinical). Secretagogue combinations (GHRH+GHRP) show clear synergy for endogenous GH/IGF‑1 release in humans, though not in conjunction with exogenous GH. GH with glutamine shows variable clinical benefit in short bowel syndrome. In vitro GH with EGF/FGF supports complementary cellular responses relevant to wound healing pages 23-25).
• Insufficient or no direct combination evidence: GH with GLP‑2/teduglutide (theoretically complementary, not yet substantiated by trials); GH with BPC‑157 or TB‑500 (no controlled combination data available in the sources reviewed) pages 23-25, clearfieldUnknownyearimmunemodulatingpeptides pages 1-27).

Practical implication: Where combination evidence exists, it is either preclinical (GH+IGF‑1) or endocrine‑axis synergy among secretagogues. For tissue‑targeted peptides such as BPC‑157 or TB‑500 and for GLP‑2 analogs, robust GH combination studies are lacking; any use should be considered investigational pending controlled trials.

Key combination study data and interpretation are summarized below.

Evidence Gaps#

Direct head-to-head comparison studies between HGH 191AA and related peptides are limited. Most comparisons are based on separate studies with different methodologies, making direct efficacy comparisons difficult.

Related Reading#

• HGH 191AA overview and research guide
• HGH 191AA research evidence
• HGH 191AA dosing protocols